PALM SPRINGS, CA — Diclofenac, a commonly prescribed nonsteroidal anti-inflammatory drug (NSAID), was shown to provide acute pain relief when administered as a nanoformulated, lower-dose formulation, ...
BALERNA, Switzerland-- (BUSINESS WIRE)--APR Applied Pharma Research’s patented formulation of Diclofenac 50 mg powder oral solution for migraine treatment and other pain areas is now available in ...
CAMBRIDGE, Mass. -- Javelin Pharmaceuticals announced at its annual analyst and institutional investor day that its US product candidate Dyloject(R) (diclofenac sodium solution for injection) ...
LAS VEGAS — An investigational submicron particle formula of the nonsteroidal anti-inflammatory drug (NSAID) diclofenac (Iroko Pharmaceuticals LLC) was effective in reducing the need for opioid rescue ...
BRIDGEWATER, N.J., April 8 Migraineurs and the physicians who treat them will soon have a new option for the acute treatment of migraine. Study results published in Cephalalgia, the international ...
This study demonstrated that lornoxicam administered as a quick-release formulation is not inferior to the equivalent formulation of diclofenac potassium in terms of onset of PAR in patients ...
The authors evaluated the effect of alcoholic beverages on the release profiles of sustained-release dosage forms containing metformin and diclofenac. More and more people who suffer from chronic ...
Notice of Allowance of Patent Application for a Non-Steroidal Anti-Inflammatory, Diclofenac Potassium, Strengthens Proprietary Position in U.S. until 2039 DBT and CAMBIA are currently protected by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results